Moonwalk Biosciences, a leading genomic medicine company, has secured $57 million in seed and Series A financing to advance its revolutionary epigenetic medicines. The funding round included participation from Alpha Wave Ventures, ARCH Venture Partners, Future Ventures, GV, Khosla Ventures, and YK Bioventures. This significant financial support will enable Moonwalk Biosciences to further develop its cutting-edge epigenetic profiling and engineering technology platform and advance its pipeline of epigenetic therapeutics for clinical use.
Epigenetics refers to the software of the genome, which determines the activation or deactivation of genes. By targeting the epigenetic code, Moonwalk Biosciences aims to reprogram cells to their healthy state, presenting a groundbreaking approach to drug discovery and development. Importantly, Moonwalk Biosciences is the first company to combine an epigenetic discovery platform with precise engineering, opening up the epigenome as a new target space for complex diseases. The company’s comprehensive read-and-write technologies utilize epigenetic engineering to develop potentially curative therapies for a wide range of diseases at their root cause level.
Moonwalk Biosciences was founded by renowned leaders in biotechnology, including Alex Aravanis, M.D., Ph.D., Arash Jamshidi, Ph.D., Justin Valley, Ph.D., and scientific co-founder Feng Zhang, Ph.D. Together, they bring decades of experience in translating complex science into clinical products. Moonwalk Biosciences’ ultimate goal is to develop effective, safe, and durable epigenetic medicines based on the most comprehensive insights into cellular epigenetics to date, covering a diverse range of indications.
Unlike traditional gene editing methods that involve altering DNA through cutting or small breaks, Moonwalk Biosciences’ epigenetic editors operate differently. They leverage the cell’s natural regulation system to precisely and permanently control multiple genes in a single step without altering the DNA sequence itself. This pioneering technique, supported by Moonwalk Biosciences’ AI-driven profiling technologies, allows the company to address multiple factors involved in complex conditions more effectively, minimizing off-target effects and toxicities while preserving the primary DNA sequence.
Moonwalk Biosciences boasts a seasoned leadership team with extensive expertise in epigenetic biology, artificial intelligence, and clinical product development. The team is well-positioned to advance the field of epigenetic engineering and pioneer new possibilities in genetic medicine by targeting the root cause of diseases.
The breakthrough technologies and insights developed by Moonwalk Biosciences hold tremendous potential for transforming the treatment landscape for a broad range of diseases. With its profound understanding of the epigenetic landscape and its precise engineering capabilities, Moonwalk Biosciences aims to redefine therapeutic approaches and open doors to potential cures previously deemed impossible. The company’s dedication to epigenome engineering represents the next frontier of genetic medicines, promising safer and more effective treatments without altering the underlying DNA sequence.
Rick Gerson, Chairman of Alpha Wave Global, expressed his enthusiasm for Moonwalk Biosciences’ approach, emphasizing that the company operates at the forefront of biology by providing a comprehensive view of the epigenome to enable precise engineering. Moonwalk Biosciences’ novel platform technology, combined with its advanced AI prediction capabilities and broad set of epigenetic engineering tools, positions the company to address unmet medical needs across various indications, including complex diseases.
With the support of its investors and the expertise of its leadership team, Moonwalk Biosciences is poised to make significant strides in the field of genetic medicine, offering new hope and potential breakthroughs for patients worldwide. As the company continues to advance its epigenetic profiling and engineering technology, the therapeutic landscape is set to undergo a transformative shift, opening up new possibilities for disease treatment and ultimately improving patient outcomes.
